1. Home
  2. EPR vs ERAS Comparison

EPR vs ERAS Comparison

Compare EPR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EPR Properties

EPR

EPR Properties

HOLD

Current Price

$61.75

Market Cap

4.6B

Sector

Real Estate

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$19.24

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPR
ERAS
Founded
1997
2018
Country
United States
United States
Employees
54
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EPR
ERAS
Price
$61.75
$19.24
Analyst Decision
Buy
Strong Buy
Analyst Count
9
12
Target Price
$58.94
$14.25
AVG Volume (30 Days)
531.8K
5.6M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
6.28%
N/A
EPS Growth
N/A
36.23
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.66
N/A
Revenue Next Year
$8.60
N/A
P/E Ratio
$25.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$48.11
$1.33
52 Week High
$63.30
$24.28

Technical Indicators

Market Signals
Indicator
EPR
ERAS
Relative Strength Index (RSI) 66.24 60.10
Support Level $57.44 $17.63
Resistance Level N/A $24.28
Average True Range (ATR) 1.03 1.29
MACD 0.26 -0.04
Stochastic Oscillator 74.10 44.27

Price Performance

Historical Comparison
EPR
ERAS

About EPR EPR Properties

EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: